Delcath Systems
$9.54
53
+$0+0% Today
Statistics
Day High
9.64
Day Low
9.31
52W High
18.1
52W Low
8.19
Volume
78,370
Avg. Volume
470,693
Mkt Cap
336.9M
P/E Ratio
109.22
Dividend Yield
-
Dividend
-
Upcoming
Earnings
12MayExpected
Expected EPS
-0.094286
Actual EPS
N/A
Financials
-70.92%Profit Margin
Unprofitable74.41MRevenue
-52.77MNet Income
Analyst Ratings
$22.00Average Price Target
The highest estimate is 30.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow DCTH. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
BlackRock Technology and Private Equity Term Trust
BTX
Mkt Cap814.64M
Johnson & Johnson
JNJ
Mkt Cap455.04B
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Merck
MRK
Mkt Cap214.76B
Pfizer
PFE
Mkt Cap140.15B
Novartis
NVS
Mkt Cap237.61B
Abbvie
ABBV
Mkt Cap385.18B
Gilead Sciences
GILD
Mkt Cap148.78B
AMGEN
AMGN
Mkt Cap160.66B
About
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Show more...
CEO
Mr. Gerard J. Michel MBA, MS
Employees
96
Country
US
ISIN
US24661P8077
Listings
0 Comments
Share your thoughts
FAQ
What is Delcath Systems stock price today?▼
The current price of DCTH is $9.54 USD — it has increased by +0% in the past 24 hours. Watch Delcath Systems stock price performance more closely on the chart.
What is Delcath Systems stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Delcath Systems stocks are traded under the ticker DCTH.
Is Delcath Systems stock price growing?▼
DCTH stock has risen by +4.49% compared to the previous week, the month change is a +6.83% rise, over the last year Delcath Systems has showed a -26.5% decrease.
What is Delcath Systems market cap?▼
Today Delcath Systems has the market capitalization of 336.9M
When is the next Delcath Systems earnings date?▼
Delcath Systems is going to release the next earnings report on May 12, 2026.
What were Delcath Systems earnings last quarter?▼
DCTH earnings for the last quarter are -0.05 USD per share, whereas the estimation was -0.06 USD resulting in a +20.62% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Delcath Systems revenue for the last year?▼
Delcath Systems revenue for the last year amounts to 74.41M USD.
What is Delcath Systems net income for the last year?▼
DCTH net income for the last year is -52.77M USD.
How many employees does Delcath Systems have?▼
As of April 02, 2026, the company has 96 employees.
In which sector is Delcath Systems located?▼
Delcath Systems operates in the Health Care sector.
When did Delcath Systems complete a stock split?▼
The last stock split for Delcath Systems was on December 24, 2019 with a ratio of 1:700.
Where is Delcath Systems headquartered?▼
Delcath Systems is headquartered in New York, US.